In today's ACT Brief, we examine the $500,000-per-day cost of execution delays and protocol variance at the point of care, ...

In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, makes the case that scaling real-time data review ...

As agentic AI, automated data harmonization, and real-time monitoring reshape clinical development, the organizations seeing ...

In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution ...

In today's ACT Brief, we examine why real-time monitoring scales only through coordinated ecosystem efforts, how ...

In today's ACT Brief, we examine how data standardization must precede real-time monitoring deployment, why contracts cannot ...

In today's ACT Brief, we examine how early assumptions govern development outcomes, why single pivotal trials require ...

In today's ACT Brief, we examine where sponsor capability gaps accumulate in protocol execution, how partnerships are ...

In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, identifies where the most consequential capability gaps accumulate—from ...

Rigid performance status cutoffs can inappropriately exclude patients whose function may improve on therapy; prespecified lower-performance cohorts and on-study functional assessments are recommended.

EHDS operationalizes MyHealth@EU and HealthData@EU to reduce Member State fragmentation through common legal, technical, and governance standards supporting secure cross-border care and research. A ...

In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, explains why the gap between data collection and analysis-ready data undermines the promise of continuous trial monitoring and what ...